Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...
Boston Scientific has agreed to acquire Penumbra in a deal worth about $14.5 billion. Boston Scientific has agreed to acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback